Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended |
Mar. 31, 2017 | Mar. 31, 2016 |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | |
Common Shares Available for Grant | | 20,700,000 | |
Compensation expense related to the company's stock-based compensation plans | | $ 30.5 | $ 32.4 |
Stock Options and SARs [Member] | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | |
Unrecognized compensation expense | | $ 86.2 | |
Weighted average period over which unrecognized compensation expense will be recognized (in years) | | 2 years 7 months 6 days | |
Stock-based compensation expense related to stock options, SAR and ESPP grants | | $ 11 | $ 13.2 |
Weighted Average Fair Values And Valuation Assumptions Used To Value Stock Option/SARs, ESPP, and Performance Units/Stock Stock-Based Compensation [Abstract] | | | |
Weighted Average Fair Value of Grants (price per share) | | $ 29.13 | $ 20.87 |
Expected Volatility (in hundredths) | | 31.67% | 36.45% |
Risk-Free Interest Rate (in hundredths) | | 1.36% | 1.03% |
Dividend Yield (in hundredths) | | 0.67% | 0.86% |
Expected Life (in years) | | 5 years 3 months 18 days | 5 years 3 months 18 days |
Stock Options and SARs Rollforward [Abstract] | | | |
Outstanding at January 1 (in shares) | | 9,850,000 | 10,744,000 |
Granted (in shares) | | 5,000 | 5,000 |
Exercised (1) (in shares) | [1] | (600,000) | (258,000) |
Forfeited (in shares) | | (99,000) | (60,000) |
Outstanding at March 31 (2) (in shares) | [2] | 9,156,000 | 10,431,000 |
Stock Options and SARs Vested or Expected to Vest (in shares) | [3] | 8,849,000 | 10,060,000 |
Stock Options and SARs Exercisable at March 31 (in shares) | [4] | 5,078,000 | 5,770,000 |
Weighted Average Grant Price Stock Option and SARs [Rollforward] | | | |
Outstanding at January 1 (price per share) | | $ 75.53 | $ 67.98 |
Granted (price per share) | | 101.61 | 69.03 |
Exercised (1) (price per share) | [1] | 57.53 | 43.44 |
Forfeited (price per share) | | 88.57 | 85.65 |
Outstanding at March 31 (2) (price per share) | [2] | 76.59 | 68.48 |
Weighted average grant price for stock options/SARs vested or expected to vest (price per share) | [3] | 76.20 | 68.04 |
Stock Options and SARs Exercisable at March 31 (price per share) | [4] | 67.74 | 58.68 |
ESPP [Member] | | | |
Weighted Average Fair Values And Valuation Assumptions Used To Value Stock Option/SARs, ESPP, and Performance Units/Stock Stock-Based Compensation [Abstract] | | | |
Weighted Average Fair Value of Grants (price per share) | | $ 24.28 | $ 17.56 |
Expected Volatility (in hundredths) | | 30.33% | 36.79% |
Risk-Free Interest Rate (in hundredths) | | 0.65% | 0.49% |
Dividend Yield (in hundredths) | | 0.69% | 0.82% |
Expected Life (in years) | | 6 months | 6 months |
Restricted Stock And Restricted Stock Units [Member] | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | |
Unrecognized compensation expense | | $ 168.5 | |
Weighted average period over which unrecognized compensation expense will be recognized (in years) | | 2 years 8 months 12 days | |
Share-Based Compensation Arrangement By Restricted Stock And Restricted Stock Units Compensation Cost | | $ 18.6 | $ 18.7 |
Restricted Stock/Restricted Stock Units and Performance Units/Performance Stock [Roll Forward] | | | |
Outstanding at January 1 (in shares) | | 3,962,000 | 4,908,000 |
Granted (in shares) | | 402,000 | 284,000 |
Released (1) (in shares) | [5] | (360,000) | (353,000) |
Forfeited (in shares) | | (82,000) | (39,000) |
Outstanding at March 31 (2) (in shares) | [6] | 3,922,000 | 4,800,000 |
Weighted Average Grant Price Restricted Stock and Restricted Stock Units/Performance Units and Performance Stock [Roll Forward] | | | |
Outstanding at January 1 (price per share) | | $ 79.63 | $ 70.35 |
Granted (price per share) | | 99.52 | 75.26 |
Released (1) (price per share) | [5] | 61.96 | 53.88 |
Forfeited (price per share) | | 82.83 | 75.35 |
Outstanding at September 30 (2) (price per share) | [6] | $ 83.22 | $ 71.81 |
Performance Units and Performance Stock [Member] | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | |
Unrecognized compensation expense | | $ 9.6 | |
Weighted average period over which unrecognized compensation expense will be recognized (in years) | | 2 years 9 months 18 days | |
Stock-based compensation expense related to stock options, SAR and ESPP grants | | $ 0.9 | $ 0.5 |
Restricted Stock/Restricted Stock Units and Performance Units/Performance Stock [Roll Forward] | | | |
Outstanding at January 1 (in shares) | | 545,290 | |
Granted (in shares) | | 118,834 | |
Released (1) (in shares) | | (89,224) | |
Outstanding at March 31 (2) (in shares) | | 574,900 | |
Weighted Average Grant Price Restricted Stock and Restricted Stock Units/Performance Units and Performance Stock [Roll Forward] | | | |
Aggregate intrinsic value of stock and units outstanding | | $ 56.1 | |
Intrinsic value of stock and units released during the year | | $ 9 | |
Performance Units and Performance Stock [Abstract] | | | |
Minimum Performance Units and Stock Allowed to be Outstanding | | 299,540 | |
Maximum Performance Units and Stock Allowed to be Outstanding | | 850,260 | |
Maximum Vest Period from the Date of Grant | | 5 years | |
Performance Period for Performance units and shares | | 3 years | |
Minimum Performance Multiple at the Completion of the Performance Period | | 0.00% | |
Maximum Performance Multiple at the Completion of the Performance Period | | 200.00% | |
Lease And Well [Member] | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | |
Compensation expense related to the company's stock-based compensation plans | | $ 10.9 | 10.4 |
Gathering And Processing Costs [Member] | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | |
Compensation expense related to the company's stock-based compensation plans | | 0.2 | 0.3 |
Exploration Costs [Member] | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | |
Compensation expense related to the company's stock-based compensation plans | | 6.2 | 6.5 |
General And Administrative [Member] | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | |
Compensation expense related to the company's stock-based compensation plans | | $ 13.2 | $ 15.2 |
| |
[1] | The total intrinsic value of stock options/SARs exercised for the three months ended March 31, 2017 and 2016 was $26.6 million and $7.3 million, respectively. The intrinsic value is based upon the difference between the market price of EOG's common stock on the date of exercise and the grant price of the stock options/SARs. | |
[2] | The total intrinsic value of stock options/SARs outstanding at March 31, 2017 and 2016 was $199.3 million and $122.1 million, respectively. At March 31, 2017 and 2016, the weighted average remaining contractual life was 3.8 years and 3.9 years, respectively. | |
[3] | The total intrinsic value of stock options/SARs vested or expected to vest at March 31, 2017 and 2016 was $196.0 million and $121.1 million, respectively. At March 31, 2017 and 2016, the weighted average remaining contractual life was 3.8 years and 3.9 years, respectively. | |
[4] | The total intrinsic value of stock options/SARs exercisable at March 31, 2017 and 2016 was $155.5 million and $108.7 million, respectively. At March 31, 2017 and 2016, the weighted average remaining contractual life was 2.4 years and 2.7 years, respectively. | |
[5] | The total intrinsic value of restricted stock and restricted stock units released for the three months ended March 31, 2017 and 2016 was $36.0 million and $24.7 million, respectively. The intrinsic value is based upon the closing price of EOG's common stock on the date the restricted stock and restricted stock units are released. | |
[6] | The total intrinsic value of restricted stock and restricted stock units outstanding at March 31, 2017 and 2016 was $382.6 million and $348.4 million, respectively. | |